AbbVie Inc. (ABBV) Depreciation & Amortization
The d&a for AbbVie Inc. (ABBV) is $8.14 Billion with a year-over-year change of -2.95%. Depreciation and Amortization (D&A) is a non-cash expense that allocates the cost of tangible and intangible assets over their useful lives.
ABBV D&A Chart
Current D&A
$8.14B
$8.14 Billion
Year-over-Year Change
-2.95%
vs. $8.39B prior year
Historical Data
17
Years of data available
Annual D&A History
| Year | D&A | YoY Change | % Change |
|---|---|---|---|
| 2025 | $8.14B | $-247.00M | -2.95% |
| 2024 | $8.39B | $-312.00M | -3.59% |
| 2023 | $8.70B | +$231.00M | +2.73% |
| 2022 | $8.47B | $-54.00M | -0.63% |
| 2021 | $8.52B | +$2.05B | +31.68% |
| 2020 | $6.47B | +$4.45B | +220.82% |
| 2019 | $2.02B | +$252.00M | +14.28% |
| 2018 | $1.76B | +$264.00M | +17.59% |
| 2017 | $1.50B | +$312.00M | +26.24% |
| 2016 | $1.19B | +$353.00M | +42.22% |
| 2015 | $836.00M | +$50.00M | +6.36% |
| 2014 | $786.00M | $-111.00M | -12.37% |
| 2013 | $897.00M | $-253.00M | -22.00% |
| 2012 | $1.15B | $-122.00M | -9.59% |
| 2011 | $1.27B | +$88.00M | +7.43% |
| 2010 | $1.18B | +$486.51M | +69.75% |
| 2009 | $697.49M | — | — |
Related Metrics
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael